Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression in p...

Descripción completa

Detalles Bibliográficos

Autores principales:	Chen-Yu Hu, Xiang-Ming Xu, Bo Hong, Zhi-Gang Wu, Yun Qian, Tian-Hao Weng, Yi-Zhi Liu, Tao-Ming Tang, Ming-Hai Wang, Hang-Ping Yao
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2019-12-01
Colección:	Frontiers in Oncology
Materias:	pancreatic cancer tyrosine kinase inhibitors RON receptor tyrosine kinase MET receptor tyrosine kinase prognosis biomarker therapeutic target
Acceso en línea:	https://www.frontiersin.org/article/10.3389/fonc.2019.01377/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!